[Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. II. In vitro combined effects of sulbactam/cefoperazone with imipenem/cilastatin, cefuzonam, flomoxef, amikacin or tobramycin].
We evaluated combined effects of sulbactam/cefoperazone (SBT/CPZ) with each of imipenem/cilastatin (IPM), cefuzonam, flomoxef, amikacin (AMK) and tobramycin (TOB) against 324 clinical strains. Through this study, we obtained the following results. 1. Against Serratia marcescens and Enterobacter cloacae, good synergism was obtained by combining SBT/CPZ with IPM, AMK, or TOB. 2. Against Pseudomonas aeruginosa, good synergism was obtained by combining SBT/CPZ with AMK or TOB. 3. When SBT/CPZ was used in combination with IPM, antagonism was observed among about 45% of strains of P. aeruginosa.
Kouda
M
M
Department of Central Clinical Laboratories, Tokyo Metropolitan Police Hospital.
Kumagai
I
I
Kobayashi
J
J
Sugai
R
R
Matsuzaki
H
H
D000583:Amikacin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D002438:Cefoperazone / Q000494:pharmacology*; D015296:Ceftizoxime / Q000031:analogs & derivatives / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D015377:Cilastatin / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000494:pharmacology; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D013407:Sulbactam / Q000494:pharmacology*; D014031:Tobramycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D015377:Cilastatin; D015378:Imipenem; D002438:Cefoperazone; D000583:Amikacin; C049934:cefuzonam; D015296:Ceftizoxime; D013407:Sulbactam; C045693:flomoxef; D014031:Tobramycin